Nanoparticulate drug delivery : perspectives on the transition from laboratory to market
Nanotechnology-based therapeutics, operating at scales of billionths of a metre, have great potential for future expansion in altering the scale and methods of drug delivery. The availability of these novel formulations to once-inaccessible areas of the body has greatly expanded the therapeutic wind...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Oxford ; Philadelphia :
Woodhead Pub.,
2012.
|
| Series: | Woodhead Publishing series in biomedicine ;
no. 17. |
| Subjects: | |
| ISBN: | 1908818190 9781908818195 9781628703825 1628703822 9781907568985 1907568980 |
| Physical Description: | 1 online resource (xiv, 229 pages) : illustrations |
Cover
Table of contents
| LEADER | 03866cam a2200457Ma 4500 | ||
|---|---|---|---|
| 001 | kn-ocn826855524 | ||
| 003 | OCoLC | ||
| 005 | 20240717213016.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 130205s2012 enka ob 001 0 eng d | ||
| 040 | |a YDXCP |b eng |e pn |c YDXCP |d OCLCO |d E7B |d IDEBK |d N$T |d OCLCF |d OPELS |d KNOVL |d COO |d OCLCQ |d KNOVL |d ZCU |d OTZ |d EBLCP |d OCLCQ |d UAB |d U3W |d D6H |d OCLCQ |d RRP |d OCLCQ |d WYU |d OCLCO |d OCLCA |d MERER |d OCLCO |d OCLCA |d OCLCQ |d OCLCA |d AUD |d OCLCO |d AU@ |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCLCA |d OCLCQ |d OCLCA |d S2H |d OCLCO |d VT2 |d OCLCO |d OCLCQ |d CASUM |d OCLCO |d OCLCL | ||
| 020 | |a 1908818190 |q (electronic bk.) | ||
| 020 | |a 9781908818195 |q (electronic bk.) | ||
| 020 | |a 9781628703825 |q (electronic bk.) | ||
| 020 | |a 1628703822 |q (electronic bk.) | ||
| 020 | |z 9781907568985 |q (hbk.) | ||
| 020 | |z 1907568980 |q (hbk.) | ||
| 035 | |a (OCoLC)826855524 |z (OCoLC)865332567 |z (OCoLC)875290958 |z (OCoLC)995041205 |z (OCoLC)1064181970 |z (OCoLC)1235840966 | ||
| 100 | 1 | |a Patravale, Vandana. | |
| 245 | 1 | 0 | |a Nanoparticulate drug delivery : |b perspectives on the transition from laboratory to market / |c Vandana Patravale, Prajakta Dandekar and Ratnesh Jain. |
| 260 | |a Oxford ; |a Philadelphia : |b Woodhead Pub., |c 2012. | ||
| 300 | |a 1 online resource (xiv, 229 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Woodhead Publishing series in biomedicine, |x 2050-0289 ; |v no. 17 | |
| 504 | |a Includes bibliographical references and index. | ||
| 506 | |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty | ||
| 520 | |a Nanotechnology-based therapeutics, operating at scales of billionths of a metre, have great potential for future expansion in altering the scale and methods of drug delivery. The availability of these novel formulations to once-inaccessible areas of the body has greatly expanded the therapeutic window of existing drug molecules. Nanoparticulate drug delivery highlights and examines the transition of nanoparticulate drug delivery systems from the laboratory into a commercially viable sector. The first chapters of the book provide an overview of the use and characterization of nanoparticulate systems as drug carriers, including the assessment of their morphology, sterility and potential toxicity. In the latter part of the book, chapters cover nanotoxicology, regulatory aspect and clinical trials, ending with an overview of several case studies and a look towards future developments. Discusses the issues surrounding nanoparticulate products, based on personal experience of their formulationProvides an overview of new application areas, including RNA interferenceOutlines the pros and cons of nanoparticulate products, and discusses how these may influence their route into the commercial sector. | ||
| 505 | 0 | |a Nanoparticulate systems as drug carriers: The need -- Nanoparticles as drug carriers -- Characterization techniques for nanoparticulate carriers -- Nanotoxicology: Evaluating toxicity potential of drug-nanoparticles -- Regulatory aspects of nanoparticulate drug delivery systems -- Clinical trials and industrial aspects -- Case studies: Nano-systems in the market. | |
| 590 | |a Knovel |b Knovel (All titles) | ||
| 650 | 0 | |a Drug delivery systems. | |
| 650 | 0 | |a Nanoparticles. | |
| 655 | 7 | |a elektronické knihy |7 fd186907 |2 czenas | |
| 655 | 9 | |a electronic books |2 eczenas | |
| 700 | 1 | |a Dandekar, Prajakta. | |
| 700 | 1 | |a Jain, Ratnesh. | |
| 776 | 0 | 8 | |i Print version: |z 9781907568985 |z 1907568980 |
| 830 | 0 | |a Woodhead Publishing series in biomedicine ; |v no. 17. |x 2050-0289 | |
| 856 | 4 | 0 | |u https://proxy.k.utb.cz/login?url=https://app.knovel.com/hotlink/toc/id:kpNDDPTLM6/nanoparticulate-drug-delivery?kpromoter=marc |y Full text |
Save to List
Cite this
Export Record
Email this